Trial Profile
Efficacy and safety of patients who received blinatumomab plus a tyrosine kinase inhibitors for relapsed/refractory (R/R) philadelphia chromosome-positive leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2017
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Bosutinib; Dasatinib; Ponatinib
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 20 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology